Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
-9.73% US12542Q700.356
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2.42 mill |
EPS: | -11.52 |
P/E: | -0.0300 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 6.80 mill |
Avg Daily Volume: | 0.870 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0300 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.0300 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
US12542Q70 0.279 - 0.433 ( +/- 21.66%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Mccormick Michael Kendrick | Buy | 20 836 | Nonstatutory Stock Option (right to buy) |
2024-01-02 | Mcdonald David | Buy | 11 365 | Nonstatutory Stock Option (right to buy) |
2024-01-02 | Feldshon Archelle Georgiou | Buy | 11 365 | Nonstatutory Stock Option (right to buy) |
2023-11-01 | Mcdonald David | Buy | 0 | |
2023-11-01 | Feldshon Archelle Georgiou | Buy | 0 |
INSIDER POWER |
---|
98.00 |
Last 90 transactions |
Buy: 3 285 386 | Sell: 12 287 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | US12542Q700.356 (-9.73% ) |
Volume | 0.413 mill |
Avg. Vol. | 0.870 mill |
% of Avg. Vol | 47.43 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.